Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00259558 |
Recruitment Status
:
Completed
First Posted
: November 29, 2005
Last Update Posted
: February 12, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to find the optimal dose of retarded release Phosphatidylcholine in the most severe form of ulcerative colitis.
The hypothesis is that ulcerative colitis (UC) is caused by a barrier dysfunction of the colonic mucus layer. The background of the study is the finding, that the phosphatidylcholine (PC) content of the colonic mucus is strongly reduced in UC compared to healthy controls and patients with Crohn´s disease. The content was meuasured in non-inflamed areas of the colon in UC. Thus, we evaluate whether a substitution of colonic PC is an effective method.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ulcerative Colitis | Drug: retarded release phosphatidylcholine | Phase 2 |
Design: prospective, randomized, double-blind, dose-finding study with retarded phosphatidylcholine.
Population: 10 patients per dose group (6 doses) - 60 patients Remark: this includes to historic groups from another study Inclusion criteria: Ulcerative Pancolitis with chronic active course and a clinical index (Rachmilewitz) over 7 and more, endoscopic index of at least 7 or more. No systemic steroids or immunosuppressants since 4 weeks.
Exclusion criteria: Pregnancy & fulminant course
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa |
Study Start Date : | April 2003 |
Study Completion Date : | March 2006 |

- Absolute change in clinical activity index (Rachmilewitz).
- Secondary end points include >50% changes in clinical and endoscopic activity index (EAI).
- Histology and life quality are reported descriptively.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 90 Years (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- chronic active ulcerative pancolitis
- course more than 4 months
- clinical index rachmilewitz 7 or more
- endoskopic index 7 or more
Exclusion Criteria:
- steroids in the last 4 weeks
- immunosuppressants in the last 4 weeks
- use of topical klymsa
- pregnancy
- fulminant course
- infectious colitis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00259558
Germany | |
Medical Hospital Unversity Heidelberg | |
Heidelberg, Germany, 69120 |
Principal Investigator: | Wolfgang Stremmel, Professor | University Heidelberg |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00259558 History of Changes |
Other Study ID Numbers: |
PC3 EC - L069/2003 BFARM - 402 2919 |
First Posted: | November 29, 2005 Key Record Dates |
Last Update Posted: | February 12, 2007 |
Last Verified: | February 2007 |
Keywords provided by Heidelberg University:
Ulcerative Colitis Dose Finding Phosphatidylcholine |
Additional relevant MeSH terms:
Colitis Ulcer Colitis, Ulcerative Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases |